Editor's note: This story was updated on Feb. 23 to include more info about the company's lead treatment. Latigo Biotherapeutics, a Thousand Oaks-based biotech firm that was originally founded by Westlake Village BioPartners, emerged from stealth mode on Feb. 14, announcing $135 million in Series A financing. Latigo is a clinical-stage biotechnology company looking to
Latigo Biotherapeutics, a Thousand Oaks-based biotech firm that was originally founded by Westlake Village BioPartners, emerged from stealth mode on Feb. 14, announcing $135 million in Series A financing. Latigo is a clinical-stage biotechnology company looking to develop non-opioid pain medicines that target pain at its source, according to a press release. Proceeds from the
Neuron23 is developing drugs that treat neurological conditions by penetrating the blood-brain barrier to reach disease targets in the central nervous system. The biotech's lead program is a Parkinson’s disease drug candidate with features that could distinguish it from rival compounds that are aiming for the same target.